LifeStance Health Group, Inc. (LFST), Wednesday announced financial results for the fourth quarter and full year ended December 31, 2025.
The company reported quarterly earnings of $11.7 million compared to a net loss of $7.1 million in the previous year. Total revenue for the quarter rose 17 percent, to $382.2 million from last year's $325.5 million.
Revenue growth in the fourth quarter was driven primarily by higher visit volumes from net clinician growth and improved clinician productivity.
For the full year 2025, earnings stood at $9.7 million, or $0.02 a share, compared with a loss of $57.4 million, or $0.15 a share, last year. Total revenue for the period amounted to $1,424.3 million, up 14 percent from $1,251.0 million in the prior year.
Moving ahead, the company sees full-year 2026 revenue of $1.615 billion to $1.655 billion, and Adjusted EBITDA of $185 million to $205 million. For the first quarter, it anticipates total revenue of $380 million to $400 million, and Adjusted EBITDA of $39 million to $45 million.
CEO Dave Bourdon announced that the Board has approved a $100 million share repurchase program, reflecting the company's strong cash generation and healthy balance sheet.
In the pre-market hours, LFST is climbing 13.73 percent, to $8.12 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.